Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma-Reference-Cited by-同舟云学术

Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma

Published:2020-01-01 Issue:1 Volume:6 Page:60
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Cercek Andrea¹,Boerner Thomas²,Tan Benjamin R.³,Chou Joanne F.⁴,Gönen Mithat⁴,Boucher Taryn M.¹,Hauser Haley F.¹,Do Richard K. G.⁵,Lowery Maeve A.¹,Harding James J.¹,Varghese Anna M.¹,Reidy-Lagunes Diane¹,Saltz Leonard¹,Schultz Nikolaus⁶,Kingham T. Peter²,D’Angelica Michael I.²,DeMatteo Ronald P.⁷,Drebin Jeffrey A.²,Allen Peter J.⁸,Balachandran Vinod P.²,Lim Kian-Huat³,Sanchez-Vega Francisco⁹,Vachharajani Neeta⁹,Majella Doyle Maria B.⁹,Fields Ryan C.⁹,Hawkins William G.⁹,Strasberg Steven M.⁹,Chapman William C.⁹,Diaz Luis A.¹,Kemeny Nancy E.¹,Jarnagin William R.²

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

2. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

3. School of Medicine, Department of Medicine, Washington University in St Louis, St Louis, Missouri

4. Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

5. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

6. Human Oncology & Pathogenesis, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York

7. Perelman School of Medicine, Department of Surgery, University of Pennsylvania, Philadelphia

8. School of Medicine, Department of Surgery, Duke University, Durham, North Carolina

9. School of Medicine, Department of Surgery, Washington University in St Louis, St Louis, Missouri

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2753558/jamaoncology_cercek_2019_oi_190075.pdf

Reference32 articles.

1. Changing international trends in mortality rates for liver, biliary and pancreatic tumours.;Khan;J Hepatol,2002

2. Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise.;Saha;Oncologist,2016

3. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.;Taylor-Robinson;Gut,2001

4. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States.;McGlynn;Cancer Epidemiol Biomarkers Prev,2006

5. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States.;Welzel;J Natl Cancer Inst,2006

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer;International Immunopharmacology;2024-03

2. Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies;Frontiers in Oncology;2024-01-24

3. Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers;Therapeutic Advances in Medical Oncology;2024-01

4. PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer;BMJ Case Reports;2023-12

5. Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis;Radiology and Oncology;2023-11-30